Global Access for Biologics in the Treatment of Severe Asthma: A Challenge to Personalized Medicine

A. Menzies-Gow, T.N. Tran, N. Hossein, N. Eleangovan, M. Rowlands, L. Bulathsinhala, Mark Hew, J. W Upham, L. G Heaney, C. Ulrik, D. Larenas-Linnemann, J. Boven, J. M. FitzGerald, M. Alacqua, E. Wang, M. Al-Ahmad, B. G. Cosio, D.J. Jackson, L. Perez de Llano, C. PorsbjergL. M. Rasmussen, J. Schmid, A. Papaioannou, Stelios Loukides, M. Kallieri, N. Lugogo, A. Tan, I. Chaudhry, V. Carter, R. Murray, D. B. Price

Research output: Contribution to journalAbstractpeer-review

Abstract

Rationale: Four different classes of monoclonal antibodies have been approved for use in severe asthma: anti-IgE (omalizumab), anti-IL-5 (mepolizumab, reslizumab), anti-IL-5Rα (benralizumab), and anti-IL-4/IL-13 (dupilumab)
Original languageEnglish
Article numberA5954
Number of pages2
JournalAmerican Journal of Respiratory and Critical Care Medicine
Volume201
Issue numberC93
DOIs
Publication statusPublished - 2020

Fingerprint Dive into the research topics of 'Global Access for Biologics in the Treatment of Severe Asthma: A Challenge to Personalized Medicine'. Together they form a unique fingerprint.

Cite this